Rakesh Jain

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The role of mechanical forces in tumor growth and therapy
    Rakesh K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114 email
    Annu Rev Biomed Eng 16:321-46. 2014
  2. pmc Solid stress facilitates spheroid formation: potential involvement of hyaluronan
    C Koike
    Edwin L Steele Laboratory, Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Br J Cancer 86:947-53. 2002
  3. pmc Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells
    C de L Davies
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, MA 02110, USA
    Br J Cancer 86:1639-44. 2002
  4. pmc Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
    Vikash P Chauhan
    1 Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA 2 School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA 3
    Nat Commun 4:2516. 2013
  5. pmc VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation
    Michelle R Dawson
    Steele Laboratory for Tumor Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e6525. 2009
  6. pmc Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
    Vikash P Chauhan
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Nanotechnol 7:383-8. 2012
  7. pmc Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
    Dushyant V Sahani
    Division of Abdominal Imaging and Intervention, Harvard Medical School and Massachusetts General Hospital, 55 Fruit Street, White 270, Boston, MA 02114, USA
    J Hematol Oncol 6:51. 2013
  8. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
  9. pmc Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers
    Rakesh K Jain
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, 100 Blossom St, COX 7, Boston, MA, USA
    J Clin Oncol 31:2205-18. 2013
  10. pmc Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease
    Shom Goel
    Edwin Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cold Spring Harb Perspect Med 2:a006486. 2012

Research Grants

Detail Information

Publications99

  1. pmc The role of mechanical forces in tumor growth and therapy
    Rakesh K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114 email
    Annu Rev Biomed Eng 16:321-46. 2014
    ..In addition, shear stresses exerted by flowing blood and interstitial fluid modulate the behavior of cancer and a variety of host cells. Taming these physical forces can improve therapeutic outcomes in many cancers. ..
  2. pmc Solid stress facilitates spheroid formation: potential involvement of hyaluronan
    C Koike
    Edwin L Steele Laboratory, Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Br J Cancer 86:947-53. 2002
    ..These findings have significant implications for tumour growth, invasion and metastasis...
  3. pmc Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells
    C de L Davies
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, MA 02110, USA
    Br J Cancer 86:1639-44. 2002
    ..Hence, caution must be exercised in extrapolating drug penetrability from spheroids and multilayer cellular sandwiches consisting of only tumour cells to tumours in vivo...
  4. pmc Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
    Vikash P Chauhan
    1 Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA 2 School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, USA 3
    Nat Commun 4:2516. 2013
    ..Thus, angiotensin inhibitors -inexpensive drugs with decades of safe use - could be rapidly repurposed as cancer therapeutics. ..
  5. pmc VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation
    Michelle R Dawson
    Steele Laboratory for Tumor Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 4:e6525. 2009
    ..Prevention of metastasis will require further identification and exploration of cellular and molecular pathways that mediate the priming of the metastatic soil...
  6. pmc Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
    Vikash P Chauhan
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Nanotechnol 7:383-8. 2012
    ..Our results further suggest that smaller (∼12 nm) nanomedicines are ideal for cancer therapy due to their superior tumour penetration...
  7. pmc Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
    Dushyant V Sahani
    Division of Abdominal Imaging and Intervention, Harvard Medical School and Massachusetts General Hospital, 55 Fruit Street, White 270, Boston, MA 02114, USA
    J Hematol Oncol 6:51. 2013
    ....
  8. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
    ..These data suggest that tumor-associated macrophages may participate in escape from antiangiogenic therapy and may represent a potential biomarker of resistance and a potential therapeutic target in recurrent glioblastoma. ..
  9. pmc Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers
    Rakesh K Jain
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, 100 Blossom St, COX 7, Boston, MA, USA
    J Clin Oncol 31:2205-18. 2013
    ..Our current efforts are directed at identifying predictive biomarkers and more-effective strategies to normalize the tumor microenvironment for enhancing anticancer therapies...
  10. pmc Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease
    Shom Goel
    Edwin Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cold Spring Harb Perspect Med 2:a006486. 2012
    ..We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions...
  11. pmc Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?
    Sergey V Kozin
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 734, Boston, MA 02114, USA
    J Natl Cancer Inst 104:899-905. 2012
    ....
  12. ncbi request reprint Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies
    Vikash P Chauhan
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Annu Rev Chem Biomol Eng 2:281-98. 2011
    ..We then highlight strategies for overcoming these barriers by modulating either drug properties or the tumor microenvironment itself to enhance the delivery and effectiveness of drugs in tumors...
  13. pmc Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Oncologist 17:212-9. 2012
    ..We measured inflammatory and angiogenic biomarkers in ADT-treated and control groups of men with prostate cancer...
  14. doi request reprint Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
    Rakesh K Jain
    Edwin L Steele Laboratory for Tumour Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 7, Boston, Massachusetts 02114, USA
    Nat Rev Cancer 8:309-16. 2008
    ....
  15. pmc Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 67:2729-35. 2007
    ..Finally, decreased fluid convection into the peritumor tissue would decrease peritumor edema associated with brain tumors and ascites accumulation in the peritoneal or pleural cavity, a major complication with a number of malignancies...
  16. pmc Delivering nanomedicine to solid tumors
    Rakesh K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 7:653-64. 2010
    ..Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors...
  17. ncbi request reprint Angiogenesis in brain tumours
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Rev Neurosci 8:610-22. 2007
    ..This creates a window of opportunity for optimally combining chemotherapeutics and radiation...
  18. ncbi request reprint Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization
    Rakesh K Jain
    Harvard Medical School and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Nat Clin Pract Cardiovasc Med 4:491-502. 2007
    ..The development of this novel approach to prevent plaque progression might add to the armamentarium of preventive measures for acute myocardial infarction, stroke and sudden cardiac death...
  19. ncbi request reprint Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    Rakesh K Jain
    Department of Radiation Oncology, Harvard Medical School, and Massachusetts General Hospital, Boston, MA 02114, USA
    Nat Clin Pract Oncol 3:24-40. 2006
    ..We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans...
  20. ncbi request reprint alphaPlGF: a new kid on the antiangiogenesis block
    Rakesh K Jain
    Steele Lab of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cell 131:443-5. 2007
    ..In this issue, Fischer et al. (2007) offer compelling evidence that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF family, has such potential in mice...
  21. pmc Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model
    Rakesh K Jain
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 5:e24. 2008
  22. pmc Biomarkers of response and resistance to antiangiogenic therapy
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 6:327-38. 2009
    ....
  23. ncbi request reprint Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  24. ncbi request reprint Antiangiogenic therapy for cancer: current and emerging concepts
    Rakesh K Jain
    E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncology (Williston Park) 19:7-16. 2005
    ..This paper reviews current and emerging concepts of the mechanism of action of antiangiogenic therapies and discusses the implications of these mechanisms for their optimal clinical use...
  25. pmc What brings pericytes to tumor vessels?
    Rakesh K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Boston, Massachusetts 02114, USA
    J Clin Invest 112:1134-6. 2003
    ..A new study (see the related article beginning on page 1142) reveals that it is not just the presence of PDGFB, but how it is presented to pericytes, that determines the quality of the endothelium-pericyte interaction...
  26. ncbi request reprint Delivery of molecular and cellular medicine to solid tumors
    R K Jain
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Control Release 53:49-67. 1998
    ....
  27. ncbi request reprint Delivery of molecular and cellular medicine to solid tumors
    R K Jain
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Adv Drug Deliv Rev 46:149-68. 2001
    ....
  28. ncbi request reprint Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function
    R K Jain
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Control Release 74:7-25. 2001
    ....
  29. ncbi request reprint Transport of molecules, particles, and cells in solid tumors
    R K Jain
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Annu Rev Biomed Eng 1:241-63. 1999
    ....
  30. ncbi request reprint Intratumoral lymphatic vessels: a case of mistaken identity or malfunction?
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 7, Boston, MA 02114, USA
    J Natl Cancer Inst 94:417-21. 2002
  31. ncbi request reprint Dissecting tumour pathophysiology using intravital microscopy
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    Nat Rev Cancer 2:266-76. 2002
    ..Intravital microscopy has provided unprecedented molecular, cellular, anatomical and functional insights into these barriers and has revealed new approaches to improved detection and treatment...
  32. pmc Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor
    R K Jain
    Edwin L Steele Laboratory, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 95:10820-5. 1998
    ..Because human tumors often relapse following hormone-ablation therapy, our data suggest that these patients may benefit from combined anti-VEGF therapy...
  33. ncbi request reprint Development. Lymphatics make the break
    Rakesh K Jain
    Edwin L Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Science 299:209-10. 2003
  34. ncbi request reprint Molecular regulation of vessel maturation
    Rakesh K Jain
    E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Med 9:685-93. 2003
    ..Normalization of the abnormal vasculature can facilitate drug delivery to tumors and formation of a mature vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering...
  35. ncbi request reprint Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  36. ncbi request reprint Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors
    Wayne L Monsky
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 8:1008-13. 2002
    ....
  37. pmc PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment
    Emmanuelle di Tomaso
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5123. 2009
    ..Here we tested the hypothesis that Platelet Derived Growth Factor-C (PDGF-C), an isoform of the PDGF family, affects GBM progression independent of VEGF pathway and hinders anti-VEGF therapy...
  38. ncbi request reprint Tumor angiogenesis and accessibility: role of vascular endothelial growth factor
    Rakesh K Jain
    Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, 100 Blossom Street Box 7, Boston, MA 02114, USA
    Semin Oncol 29:3-9. 2002
    ....
  39. pmc Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer
    Lei Xu
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 69:7905-10. 2009
    ..These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy...
  40. doi request reprint Angiogenesis as a therapeutic target in malignant gliomas
    Andrew S Chi
    Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 14:621-36. 2009
    ..Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients...
  41. ncbi request reprint Lymphatic metastasis in the absence of functional intratumor lymphatics
    Timothy P Padera
    E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Science 296:1883-6. 2002
    ..These findings suggest that the functional lymphatics in the tumor margin alone are sufficient for lymphatic metastasis and should be targeted therapeutically...
  42. pmc AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    Tracy T Batchelor
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Cell 11:83-95. 2007
    ..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...
  43. ncbi request reprint Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mouse
    Peigen Huang
    Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Comp Med 55:236-43. 2005
    ..This in vitro and in vivo transplantable and metastatic osteosarcoma (Os-P0107) is an attractive model for further study of tumor pathophysiology and treatment efficiency affecting VEGF expression...
  44. pmc Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis
    Johanna Lahdenranta
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 69:2801-8. 2009
    ..Our findings explain the correlation between NOS and lymphatic metastasis seen in a number of human tumors and open the door for potential therapies exploiting NO signaling to treat diseases of the lymphatic system...
  45. doi request reprint Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors
    Hon Kit Wong
    Department of Radiation Oncology, Steele Laboratory, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer Res 70:3483-93. 2010
    ..This study shows that anti-VEGF therapy normalizes the vasculature of schwannoma xenografts in nude mice and successfully controls the tumor growth, probably by reestablishing a natural balance between VEGF and semaphorin 3 signaling...
  46. ncbi request reprint Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors
    Sergey V Kozin
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 67:5076-82. 2007
    ..Our findings suggest that antiangiogenic agents could be effective in the treatment of patients with relapses after radiotherapy...
  47. pmc Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:3020-6. 2009
    ..To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response...
  48. pmc Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation
    Sergey V Kozin
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 70:5679-85. 2010
    ..Our results suggest that an increase in intratumoral SDF-1alpha triggered by LI recruits myelomonocytes/macrophages which promotes tumor regrowth...
  49. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  50. ncbi request reprint Differential gene expression in metastasizing cells shed from kidney tumors
    Maximilian Bockhorn
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2469-73. 2004
    ..Furthermore, resistance to apoptosis may enhance metastasis in the higher metastatic tumor...
  51. ncbi request reprint Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers
    Emmanuelle di Tomaso
    Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer Res 65:5740-9. 2005
    ..More than 80% of the defects lacked immunoreactivity for multiple basement membrane proteins...
  52. ncbi request reprint Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
    Ricky T Tong
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 64:3731-6. 2004
    ..Thus, vascular normalization may contribute to the improved survival rates in tumor-bearing animals and in colorectal carcinoma patients treated with an anti-VEGF antibody in combination with cytotoxic therapies...
  53. pmc Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo
    Mark Stroh
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Med 11:678-82. 2005
    ..These examples show the versatility of quantum dots for studying tumor pathophysiology and creating avenues for treatment...
  54. ncbi request reprint Taming vessels to treat cancer
    Rakesh K Jain
    Radiation Oncology Department, Massachusetts General Hospital and Harvard Medical School, USA
    Sci Am 298:56-63. 2008
  55. pmc Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo
    Patrick Au
    Department of RadiationOncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Am J Pathol 175:294-302. 2009
    ..These results suggest a potential negative interaction between angiogenic growth factors and vascular cells; their use in combination should be carefully tested in vivo for such opposing effects...
  56. pmc Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors
    Dan G Duda
    Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, COX 734, 100 Blossom St, Boston, MA 02114, USA
    Blood 107:2774-6. 2006
    ..We demonstrate that BMD-ECs incorporate in perfused tumor vessels, and that this contribution varies with organ site and mouse strain...
  57. ncbi request reprint Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF
    Lei Xu
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Biol Chem 277:11368-74. 2002
    ..These results show that acidic pH activates Ras and the ERK1/2 MAPK pathway to enhance VEGF transcription via AP-1, leading to increased VEGF production...
  58. pmc Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice
    Walid S Kamoun
    Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:2542-52. 2009
    ..Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice...
  59. ncbi request reprint Tumour biology: herceptin acts as an anti-angiogenic cocktail
    Yotaro Izumi
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Nature 416:279-80. 2002
    ..As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments...
  60. pmc NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels
    Satoshi Kashiwagi
    Edwin L Steele Laboratory, Department of Radiation Oncology, and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Invest 115:1816-27. 2005
    ..These data indicate that endothelial cell-derived NO induces mural cell recruitment as well as subsequent morphogenesis and stabilization of angiogenic vessels...
  61. pmc Diffusion and convection in collagen gels: implications for transport in the tumor interstitium
    Saroja Ramanujan
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Biophys J 83:1650-60. 2002
    ..These findings have significant implications for drug delivery in tumors and for tissue engineering applications...
  62. pmc Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    Elizabeth R Gerstner
    Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Neuro Oncol 12:466-72. 2010
    ..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies...
  63. pmc Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    Neuro Oncol 11:853-60. 2009
    ..Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia...
  64. ncbi request reprint Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions
    Timothy P Padera
    Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Imaging 1:9-15. 2002
    ..Future applications will include the use of MPLSM in combination with fluorescent reporters to give novel insight into the regulation and function of genes...
  65. ncbi request reprint Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts
    Yotaro Izumi
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 63:747-51. 2003
    ..Although passaged tumors behave differently, it is encouraging that the tumor growth rates under DC101 treatment are comparable among different passage generations...
  66. ncbi request reprint A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy
    Brian R Stoll
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Blood 102:2555-61. 2003
    ..The model offers new insight into tumor angiogenesis with implications for the rational design of antiangiogenic therapy...
  67. pmc Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis
    Dai Fukumura
    Edwin L Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
    Circ Res 93:e88-97. 2003
    ..The full text of this article is available online at http://www.circresaha.org...
  68. pmc Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib
    Timothy P Padera
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Mol Cancer Ther 7:2272-9. 2008
    ..Collectively, these data indicate that the response of lymphatic vessels to a TKI can determine the incidence of lymphatic metastasis, independent of the effect of the TKI on blood vessels...
  69. ncbi request reprint Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
    George Alexandrakis
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Med 10:203-7. 2004
    ..The ratio of these two components depends on molecular size and can be altered in vivo with hyaluronidase and collagenase. These studies indicate that TPFCM is a promising tool to dissect the barriers to drug delivery in tumors...
  70. pmc In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts
    Jean Y Perentes
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Methods 6:143-5. 2009
    ..We show that the matrix-modifying hormone relaxin increased tumor-associated fibroblast (TAF) interaction with collagen fibers by stimulating beta1-integrin activity, which is necessary for fiber remodeling by matrix metalloproteinases...
  71. pmc Targeted therapy in rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27705, USA
    Oncology (Williston Park) 21:1055-65; discussion 1065, 1070, 1075 passim. 2007
    ..This review will address completed and ongoing trials that have established and continue to clarify the effects of these agents in rectal cancer...
  72. ncbi request reprint Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications
    Tohru Hoshida
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Res 66:8065-75. 2006
    ....
  73. doi request reprint Perivascular nitric oxide gradients normalize tumor vasculature
    Satoshi Kashiwagi
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Med 14:255-7. 2008
    ..Creation of perivascular NO gradients may be an effective strategy for normalizing abnormal vasculature...
  74. ncbi request reprint Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
    ..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine...
  75. ncbi request reprint Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma
    Lei Xu
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 7, Boston, MA 02114, USA
    Mol Cancer Res 5:873-80. 2007
    ....
  76. ncbi request reprint The role of nitric oxide in tumour progression
    Dai Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Rev Cancer 6:521-34. 2006
    ..We also discuss potential strategies for cancer treatment that modulate NO production and/or its downstream signalling pathways...
  77. pmc Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization
    Dai Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street Cox 7, Boston, MA 02114, USA
    Microvasc Res 74:72-84. 2007
    ..Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect...
  78. pmc Imaging angiogenesis and the microenvironment
    Dai Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    APMIS 116:695-715. 2008
    ..Restoring the balance of pro- and anti-angiogenic factors in tumors may "normalize" tumor vasculature and thus improve its function. Administration of cytotoxic therapy during the vascular normalization would enhance its efficacy...
  79. pmc Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models
    Dai Fukumura
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Microcirculation 17:206-25. 2010
    ..Administration of cytotoxic therapy during periods of vascular normalization has the potential to enhance treatment efficacy...
  80. doi request reprint VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Nat Rev Clin Oncol 6:229-36. 2009
    ..Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites...
  81. pmc Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice
    Peigen Huang
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Comp Med 58:253-63. 2008
    ..Establishment of these novel tumor lines will benefit both in vivo and in vitro studies on the pathophysiology of cancer in this relatively new but widely used mouse strain...
  82. ncbi request reprint Irradiation reduces interstitial fluid transport and increases the collagen content in tumors
    Cynthia A Znati
    Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 9:5508-13. 2003
    ..To test the hypothesis that radiation alters tumor interstitial transport, we measured tumor hydraulic conductivity (K) and hyaluronan and collagen type I levels after irradiation...
  83. ncbi request reprint Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models
    Lei Xu
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 66:3971-7. 2006
    ..Our study shows that PlGF overexpression decreases VEGF homodimer formation and inhibits tumor progression...
  84. ncbi request reprint Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize
    Dai Fukumura
    Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Cell Biochem 101:937-49. 2007
    ..Combined anti-angiogenic and conventional therapies have shown promise in the clinic...
  85. ncbi request reprint Differential transplantability of tumor-associated stromal cells
    Dan G Duda
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 64:5920-4. 2004
    ..These studies of tumor tissue transplantation provide a platform for exploring the role of epithelial-stromal interactions in studies of tumor heterogeneity and drug resistance...
  86. ncbi request reprint A 2-D/3-D model-based method to quantify the complexity of microvasculature imaged by in vivo multiphoton microscopy
    James A Tyrrell
    Department of Electrical, Computer and Systems Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180 3590, USA
    Microvasc Res 70:165-78. 2005
    ..The resulting measures are expressed in units of information (bits). Synthetic and real-data examples are provided to illustrate the proposed measures...
  87. pmc VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
    Trends Mol Med 13:223-30. 2007
    ....
  88. ncbi request reprint VEGFR3: a new target for antiangiogenesis therapy?
    Timothy P Padera
    Edwin L Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Dev Cell 15:178-9. 2008
    ..Tammela et al. in Nature show that VEGFR-3, via Notch regulation, is present on endothelial tip cells and is critical to sprouting angiogenesis...
  89. pmc Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy
    Dan G Duda
    Steele Laboratory for Tumor Biology, Department of Radiation Oncology and Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 24:1449-53. 2006
    ..CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancer patients remains unclear...
  90. ncbi request reprint Pathology: cancer cells compress intratumour vessels
    Timothy P Padera
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 427:695. 2004
    ..By reducing this compressive mechanical force and opening vessels, cytotoxic cancer treatments have the potential to increase blood perfusion, thereby improving drug delivery...
  91. ncbi request reprint Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus
    Wilson Mok
    Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 67:10664-8. 2007
    ..Thus, these findings introduce a new approach to improve the delivery and efficacy of oncolytic viral vectors: modulation of tumor glycosaminoglycans to enhance convection...
  92. ncbi request reprint Measurement of macromolecular diffusion coefficients in human tumors
    Edward B Brown
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Boston, MA 02114, USA
    Microvasc Res 67:231-6. 2004
    ..These measurements should help in modeling the transport of novel large MW therapeutics, and hence in estimating their distribution and efficacy in tumors...
  93. ncbi request reprint Small blood vessel engineering
    Patrick Au
    Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Methods Mol Med 140:183-95. 2007
    ..The engineered vessels are stable and functional, and they persist for more than 1 year in vivo. This approach may potentially lead to the creation of a well-vascularized-engineered tissue...
  94. pmc Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow
    Dan G Duda
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Invest 115:596-8. 2005
    ....
  95. ncbi request reprint Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
    Christopher G Willett
    J Clin Oncol 23:8136-9. 2005
  96. ncbi request reprint The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
    Igor Garkavtsev
    Edwin L Steele Laboratory for Tumour Biology, Department of Radiation Oncology Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 428:328-32. 2004
    ..These results indicate that ING4 has an important role in brain tumour pathogenesis...
  97. pmc Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:4033-42. 2007
    ..Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic...
  98. ncbi request reprint Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant site
    Takeshi Gohongi
    Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba shi 305 8575, Japan
    Oncol Rep 11:803-7. 2004
    ..The results of the present study together with our previous study imply that the primary tumor microenvironment is conducive to the angiogenesis at a distant site by the production of the endogenous angiogenesis inhibitor TGFbeta1...
  99. ncbi request reprint Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model
    Lei Xu
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 65:5711-9. 2005
    ....

Research Grants18

  1. Conference on Angiogenesis in Cancer and Other Diseases
    Rakesh Jain; Fiscal Year: 2002
    ..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..
  2. Probing Tumor Microenvironment Using Nanotechnology
    Rakesh K Jain; Fiscal Year: 2010
    ..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..
  3. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh K Jain; Fiscal Year: 2010
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  4. Integrative Biology of Tumor Metastasis
    Rakesh Jain; Fiscal Year: 2009
    ..Finally, we have the resources and the clinical collaborators in place to initiate a clinical trial based on our findings, as attested by our ongoing trial using a VEGF-specific antibody. ..
  5. Probing Tumor Microenvironment Using Nanotechnology
    Rakesh Jain; Fiscal Year: 2009
    ..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..
  6. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh Jain; Fiscal Year: 2009
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  7. Training Program in Pathophysiology of Solid Tumors
    Rakesh Jain; Fiscal Year: 2007
    ..abstract_text> ..
  8. Integrative Biology of Tumor Metastasis
    Rakesh Jain; Fiscal Year: 2007
    ..Finally, we have the resources and the clinical collaborators in place to initiate a clinical trial based on our findings, as attested by our ongoing trial using a VEGF-specific antibody. ..
  9. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh Jain; Fiscal Year: 2007
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  10. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh Jain; Fiscal Year: 2006
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  11. Integrative Biology of Tumor Metastasis
    Rakesh Jain; Fiscal Year: 2006
    ..Finally, we have the resources and the clinical collaborators in place to initiate a clinical trial based on our findings, as attested by our ongoing trial using a VEGF-specific antibody. ..
  12. Anti-Angiogenesis/Drugs in Tumors--Bench /Bedside & Back
    Rakesh Jain; Fiscal Year: 2005
    ..Attendance at this conference will provide an excellent opportunity for young investigators working on cancer to educate and familiarize themselves with the field of angiogenesis and the complexities of the system. ..
  13. Probing Tumor Microenvironment Using Nanotechnology
    Rakesh Jain; Fiscal Year: 2009
    ..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..